Bipolar and Related Disorders Clinical Trial
Official title:
Study About the Effectiveness of Enhancing Cognitive Reserve in Children, Adolescents and Young Adults at Genetic Risk for Psychosis
The high hereditary component and the contribution of neurodevelopmental processes in bipolar disorder and schizophrenia means implies the children of these patients are considered a high risk population for both diseases and therefore a very adequate sample for the study of vulnerability markers to both disorders. To date there is no previous literature on the psychological approach of children and adolescents of bipolar or schizophrenic patients. The concept of cognitive reserve (CR) was initially developed in the field of dementia, it assumes that people with the same brain damage may have different clinical manifestations depending on their ability to compensate for this damage, so a greater cognitive reserve will entail a greater capacity to compensate the alterations and difficulties due to the pathology. Enhancing CR in high genetic risk population could help the acquisition of skills that help compensate the clinical, cognitive and neuroimaging alterations and ultimately help in the prevention of the development of pathologies for those with higher risk.This study aims to develop and apply a psychological program in order to enhance cognitive reserve (CR) in child, adolescent and young adults offspring of patients diagnosed with schizophrenia or bipolar disorder (SZBP-OFF).
Status | Recruiting |
Enrollment | 173 |
Est. completion date | June 2022 |
Est. primary completion date | February 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 6 Years to 25 Years |
Eligibility | Inclusion Criteria (Off-spring of patients) Inclusion criteria (Offsprings) - Children, adolescents or young adults of both genders aged from 6 to 25, with the father and / or mother with schizophrenia, schizoaffective disorder or bipolar disorder according to DSM-IV criteria. - Informed consent signed by their parents or legal guardians by adolescents if they are under 12 years old. Inclusion criteria (Controls) - Children, adolescents or young adults of both genders between the ages of 6 and 25 years. - No history of psychotic disorder or bipolar disorder in first and second degree relatives. - Consent signed by the parents or legal guardians if they are under 12 years old. Exclusion Criteria: • Mental retardation with impaired functioning and presence of neurological disorder or history of traumatic brain injury with loss of consciousness. |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Clinic | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Hospital Clinic of Barcelona | Consorcio Centro de Investigación Biomédica en Red, M.P., Institut d'Investigacions Biomèdiques August Pi i Sunyer, Instituto de Salud Carlos III |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Cognitive reserve | Changes in cognitive reserve assessed with a specific scale which assesses the most common proposed proxy indicators such as education-occupation' which is assessed taking into account the number of years of obligatory education that subjects completed and parent's educational level; and the lifetime school performance and lifetime participation in leisure, social and physical activities. | 3 months afther the intervention and 12 months after baseline | |
Secondary | Hamilton Depression Rating Scale (HDRS-21) | Scale to assess depression symptoms. Score between 0 to 7 indicates absence of depressive symptoms, hihher scores indicate more severe depression. | After the intervention (3 months) and 1 year after baseline | |
Secondary | Young Mania Rating Scale (YMRS) | The YMRS is a rating scale used to evaluate manic symptoms at baseline and over time in individuals with mania. Scores superior to 12 indicate presence of manic episodes. Higher scores indicate more severe mania. | After the intervention (3 months) and 1 year after baseline | |
Secondary | Bipolar Prodrome Symptom Interview and Scale_Prospective (BPSS_FP) | It is a specific interview for emerging bipolar disorder symptoms. | 12 months after baseline | |
Secondary | Continuous Performance Test | Sustained attention test | After the intervention (3 months) and 12 months after baseline | |
Secondary | Wisconsin Card Sorting Test | Executive function test (set-shifting, flexibility) | After the intervention (3 months) and 12 months after baseline | |
Secondary | Stroop Test | Executive function test (inhibit interference) | After the intervention (3 months) and 12 months after baseline | |
Secondary | Neuroimage variables | Changes in white and grey matter. Measure will be performed with a MRI | After the intervention (3 months) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06408012 -
An Innovative Master Platform for Clinical Trials in Mood Disorders
|
||
Completed |
NCT05601063 -
Ascertaining Diagnosis Classification With Elicited Speech
|
||
Recruiting |
NCT06002204 -
Studying the Health of Asians to Advance Knowledge, Treatments, and Interventions for Depression
|
||
Not yet recruiting |
NCT06426134 -
Ketosis Impact on Signs & Symptoms of Schizophrenia and Bipolar disorderS
|
N/A | |
Not yet recruiting |
NCT05705063 -
Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar Illness
|
N/A | |
Completed |
NCT03152032 -
Employment Outcomes After Vocational Training
|
N/A |